Stay updated with breaking news from Protect Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This quality improvement study evaluates whether implementation of a decolonization collaborative is associated with reduced regional multidrug-resistant
Los Angeles, California, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (TLI) is pleased to announce that Lundquist Investigator Loren Miller, MD,
The award recognizes the Protect Trial, a clinical trial jointly led by Dr. Miller and senior investigator Susan Huang, MD, MPH, Chancellor’s Professor at...
In the PROTECT trial, teplizumab preserved β-cell function in newly diagnosed type 1 diabetes patients, slowing the decline of C-peptide levels, but key secondary endpoints, such as time in range and HbA1c, showed numerical trends without statistical significance.